FLT3 and acute myeloid leukemia: In the subgroup of patients aged over 60 years, FLT3-ITD AML was associated with significantly shorter RFS compared to wild-type FLT3 (5.2 vs. 7.8 months, p = 0.033) (Figure 2C).